Sign up to save your podcasts
Or
Share Miguel-Angel Perales, MD - Shifting Gears in Treating Relapsed and Refractory Indolent B-Cell Lymphomas: Where Do CAR T Cell Therapies Stand in FL and CLL/SLL?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Miguel-Angel Perales, MD - Shifting Gears in Treating Relapsed and Refractory Indolent B-Cell Lymphomas: Where Do CAR T Cell Therapies Stand in FL and CLL/SLL?
Please visit answersincme.com/FSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancer discusses the use of chimeric antigen receptor (CAR) T cell therapies in B-cell lymphoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using chimeric antigen receptor (CAR) T cell therapies for relapsed/refractory indolent follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); Describe the clinical profiles of approved and emerging CD19-directed CAR T cell therapies for relapsed/refractory indolent FL and CLL/SLL; and Outline clinical considerations for the use of CD19-directed CAR T cell therapies for relapsed/refractory indolent FL and CLL/SLL.
View all episodes
By Answers in CME
5
77 ratings
Please visit answersincme.com/FSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancer discusses the use of chimeric antigen receptor (CAR) T cell therapies in B-cell lymphoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using chimeric antigen receptor (CAR) T cell therapies for relapsed/refractory indolent follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); Describe the clinical profiles of approved and emerging CD19-directed CAR T cell therapies for relapsed/refractory indolent FL and CLL/SLL; and Outline clinical considerations for the use of CD19-directed CAR T cell therapies for relapsed/refractory indolent FL and CLL/SLL.
More shows like CME in Minutes: Education in Oncology & Hematology
View all
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Breast Cancer Update
66 Listeners
Research To Practice | Oncology Videos
121 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
11 Listeners
ASCO Daily News
57 Listeners
The Curbsiders Internal Medicine Podcast
3,360 Listeners
The ONS Podcast
205 Listeners
The Daily Show: Ears Edition
14,310 Listeners
OncLive® On Air
22 Listeners
The Clinical Problem Solvers
514 Listeners
Blood Podcast
52 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
9,935 Listeners
Oncology Today with Dr Neil Love
59 Listeners
Two Onc Docs
193 Listeners
CME in Minutes: Education in Dermatology
3 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
43 Listeners
CME in Minutes: Education in Ophthalmology
0 Listeners
CME in Minutes: Education in Cardiology & Pulmonology
3 Listeners
CME in Minutes: Education in Primary Care
6 Listeners
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
4 Listeners